Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Quince Therapeutics Inc.

Quince Therapeutics ( ($QNCX) ) has released its Q3 earnings. Here is a breakdown of the information Quince Therapeutics presented to its investors...

Current Quarter	$-0.2	Next Quarter	$-0.15
Current Year	$-1.07	Next Year	$-0.66
QoQ Growth	+25.0%	YoY Growth	+38.3%
3Y EPS CAGR	N/A	Target Price	$7.40
Consensus	Buy	Upside	+245.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	QNCX	$2.14	+4.90%	517.89K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QNCX	$2.14	+4.9%	517.89K
3
4
5
6

QNCX

QNCX

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Quince Therapeutics Inc. Data in Excel

Get Quince Therapeutics Inc. Data in Excel